News

Article

ABITEC Enters into Memorandum of Understanding with Luca AICell

The memorandum of understanding between ABITEC and Luca AICell will work to advance ultra-high purity lipidic chemistries.

ABITEC, a subsidiary of ABF Ingredients, announced a memorandum of understanding (MoU) agreement with Luca AICell, a bio-platform technology company, on Sept. 10, 2021.This MoU supports an agreement to pursue foundational research that aims to advance the use of ultra-high purity lipidic chemistries across various disciplines.

Luca AICell developed a proprietary artificial cell membrane technology, the LUCA Lipid Bilayer-LLBTM, that uses artificial intelligence to optimize their nano-assembly technology. Per an ABITEC press release, this allows them to work with various types of unique functional lipids and apply optimal formulation ratios to create artificial membranes.

“Lipid nanoparticle technology is a drug delivery system that injects various vaccines and active drugs into our body to ensure that the substance is maintained in different physiological environments and protected to reach the target point,” said Nam-Joon Choo, the developer of the artificial membrane technology at Luca AICEll, in the press release. “Through this joint research collaboration and business partnership (commercialization) with ABITEC, it is not only possible to produce mRNA [messenger RNA] vaccines, but also possible to establish a standard platform technology that composes a delivery system suitable for the characteristics and administration purpose of various infectious disease vaccines.”

“It is through visionary collaborations with [organizations] such as Luca AICell that has provided ABITEC the opportunity to expand our focus towards basic science, as opposed to historic short-term commercial drivers.” said Donal Kelemen, global business director for ABITEC, in the press release.“We believe this directional approach towards innovation is paramount to the development of impactful lipid products and their associated applications to further understand and address the scientific and biological challenges facing the market sectors that we serve today and tomorrow.”

Source: ABITEC

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content